Mitsue Mariam Zaman

[Mitsue Mariam Zaman @Mitz_Z]

Sometimes it's okay to not know. And sometimes it's okay to be a square peg in a round hole.
#UofTNextSteps
#nervous #excited

[Mitsue Mariam Zaman @Mitz_Z]

Every time I step out of home, I'll return with 1 more connection! #UofTNextSteps

[Mitsue Mariam Zaman @Mitz_Z]

OXGN announced European patent issuance for Oxi4503 in AML and other Myeloid malignancies. http://t.co/iy9nU0e6pC
#hmb301

[Mitsue Mariam Zaman @Mitz_Z]

High approval chance for OXGN combo as non-chemo equivalent for breast cancer- Improving pts quality of life!!#hmb301
http://t.co/gWkJSufzhr

[Mitsue Mariam Zaman @Mitz_Z]

This might be a reason why OXGN is dropping- http://t.co/T6a2De3mLo
#hmb301

[Mitsue Mariam Zaman @Mitz_Z]

After a week of green, OXGN just crashed down by 8.65% #hmb301

[Mitsue Mariam Zaman @Mitz_Z]

OXGN to release results of its Phase 2 study of fosbretabulin in combination with bevacizumab on November 9. #hmb301
http://t.co/OXAMrCCQzJ

[Mitsue Mariam Zaman @Mitz_Z]

OXGN up by 6.88% soon after Cancer Medicine publishes article on the incredible potential of OXi4503 ! #hmb301
http://t.co/SwjNO5jgDT

[Mitsue Mariam Zaman @Mitz_Z]

OXGN up by 3.27% to finish at $2.21. Hope this upward trend will continue! #hmb301